As every year when fall sets in after the somewhat slower summer days, the women's health innovation ecosystem is currently experiencing a noticeable uptick in investment activity.
So today I thought's we'd take a closer look at last month's investment activity, and see if we can identify emerging trends or forecast potential developments for the remainder of the year, and beyond.
Ready? Let's do it!
Investment Summary
September 2024 saw 13 key women's health investments, totaling approximately $106 million (excluding Organon's potential $1.2B acquisition). Here's the breakdown:
- Hyivy Health: $2M seed funding for smart pelvic health device
- Helaina: $45M Series B for human bioactive proteins in infant nutrition
- Cercle: $6M seed funding for AI-driven women's healthcare platform
- Harbor: $7M seed funding for smart baby monitor
- Canopie: $3.7M seed funding for maternal mental health platform
- Luminate: $15M Series A for chemotherapy side effect management
- Organon: Potential $1.2B acquisition of Dermavant Sciences (dermatology)
- Vivian Lab: €300K seed funding for menopause care in Germany
- HeyFlow: £235K investment for workplace reproductive health inclusion
- Bloomlife: $12.2M Series A for remote maternal care platform
- Hello Inside: €1.65M seed funding for metabolic health using CGM data
- Laiqa Wellness: $1.78M seed funding for hormonal health in India
- Melodi Health: $10.75M Series A for breast reconstruction technology
Diversification: A Sign of Market Maturity
When reviewing this list of September 2024 investments, we see that they span a wide range of women's health areas. One could argue that this is a signal of market maturity and investors' growing recognition of women's health as a multifaceted field, that extends beyond traditional focus areas like reproductive health.
It seems like the investor mindset is starting to evolve, and the far too common objection "I've already invested in a women's health company" is becoming one less frequently used. Instead, we're seeing more and more repeat investors in the category who understand the sector's diversity, and are increasingly placing more than one bet. This shift points to an increased sophistication in understanding women's health investment opportunities.
The number of investments in specialized solutions, however, also raises questions about the future of so-called point solutions versus platform companies. While there's an overall trend towards comprehensive platforms, the market likely needs and can support both integrated care solutions and focused, best-in-class point solutions.
For startups at this point in time, the key is to critically assess their position: Can they dominate their niche, or should they aim for a broader platform status? Excellence in a specific area can make a company an attractive acquisition target for larger platforms or strategic players like pharma or medtech companies.
The Quiet Consolidation
While major acquisitions like Organon's potential $1.2B deal with Dermavant Sciences grab headlines, a subtler consolidation trend is unfolding. Women's health companies are quietly merging, being acquired, or closing down beyond media attention, reshaping the competitive landscape in less visible but significant ways.
An while an outlier, the Organon-Dermavant deal is noteworthy. Not just for its size, but for what it represents. It's another indicator that major players are viewing women's health more holistically, moving beyond reproductive health. This shift could have implications for future investments and more moves from investments in "just woman's health aka reproductive health" to a more holistic approach of investing in "the health of women".
Evolving Investment Criteria
Funded later-stage companies seem to share characteristics that differ from the direct-to-consumer models prevalent in the COVID/post-COVID years, as investor priorities have changed:
- Solid reimbursement strategies: Investors prioritize companies demonstrating clear paths to integration with existing healthcare payment systems.
- Impactful AI integration: Investors seek companies leveraging AI to meaningfully improve healthcare delivery and efficiency or patient outcomes.
- Strong evidence of impact: Investors look for robust data demonstrating both clinical and economic impact.
The Category Gains Momentum Beyond the US
While most deals are still concentrated in the U.S., we're seeing the women's health category gaining momentum globally. This isn't just about U.S. companies expanding internationally, but the rise of local players in various markets worldwide.
Undoubtedly significant untapped markets exist outside North America and Europe, and the potential for impact is becoming clearer to investors in those geographies.
Global expansion comes with challenges. Cultural differences, varying healthcare systems, and complex regulatory landscapes mean solutions need to be tailored to local contexts, which creates opportunities for companies, who excel in their local markets, and become interesting acquisition targets for larger organizations looking to grow their geographic footprint, as we have seen in previous months.
Looking Ahead
As we enter the final quarter of 2024, the women's health innovation landscape continues to evolve rapidly. The trends we've observed - from diversification and quiet consolidation to evolving investment criteria and global expansion - are shaping a sector that's slowly maturing but also still ripe with opportunity.
Yes, the challenges ahead are significant, but so are the possibilities, and companies that can successfully navigate complex reimbursement landscapes, prove their value through robust data, and scale across diverse global markets are positioning themselves to lead in reshaping women's health.
The potential for meaningful impact in women's health remains large, and as the sector matures and investors become more sophisticated, we may see even more targeted and impactful investments in the coming months and years.
At Femtech Insider, we'll of course continue to closely monitor these developments, tracking not just the headline-grabbing deals, but also the quieter trends and emerging players driving innovation in women's health. The journey of women's health innovation is far from over - in fact, it feels like we're just getting started.
